Developer docs
API playgroundTry for free, no card

Search company profiles

Synthesis Capital

Full company profile

uuid0000p4h

Namestring
Synthesis Capital
Legal namestring
Synthesis Capital LLP
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Synthesis Capital LLP is a London-based, FCA-regulated venture capital firm founded in 2020 that invests exclusively in food technology companies from seed through Series C. The firm manages over $300M in assets under management, claims 14+ years of investing experience at the leading edge of food technology, and focuses on technologies that replace animal products across the food supply chain — spanning cultivated meat, plant-based proteins, precision and continuous fermentation, synthetic fats, and cell-line screening.

The firm's product is a single investment platform (Synthesis Capital Fund I LP) deployed across approximately 10 disclosed portfolio companies, including Equinom, Hyfé, Redefine Meat, Savor, Pow.Bio, New Culture, Upside Foods, Culture Biosciences, Perfect Day, and Triplebar. Synthesis Capital typically leads or co-leads Series A and B rounds, partners with high-profile co-investors (Temasek, Abu Dhabi Growth Fund, Breakthrough Energy Ventures, The Production Board), and provides hands-on post-investment support including board leadership and ESG integration. The firm operates with fewer than 10 employees, is co-led by Managing Partner Costa Yiannoulis and Partner Rosie Wardle, and maintains the Guernsey Green Fund designation and UN PRI signatory status as core institutional credibility markers.

Synthesis Capital's revenue model follows the standard venture capital structure: recurring management fees charged on committed capital under investment advisory agreements, supplemented by performance-based carried interest tied to fund returns. The firm does not sell technology products and generates no transactional product revenue; the underlying asset base (AUM), LP composition, and fund performance cycle are the principal value drivers. Distribution and deal sourcing occur through founder networks, co-investor syndicates, and direct outreach, with thought-leadership content and conference presence supporting top-of-funnel brand building.

Short descriptiontext

Synthesis Capital is a London-based, FCA-regulated venture capital firm managing $300M+ in assets and focused exclusively on seed-to-Series-C food technology companies developing alternative proteins, fermentation, and synthetic fat platforms to replace animal products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, food technology investments, alternative protein funding, impact venture capital, early stage growth capital
Industry2 codes
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)
SECONDARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
NAICS code1 code
  • Other Financial Investment Activities5239
Product category
Venture Capital (Food Technology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees
TypeSubscription Recurring
Description

As a venture capital firm managing over $300M in assets under management, Synthesis Capital generates revenue through management fees charged on committed capital under its investment advisory agreements. These fees support the firm's operations and investment activities.

synthesis.capital
2Carried Interest (Performance Fees)
TypeSubscription Recurring
Description

The firm operates a long-term carried interest incentive plan for eligible team members after 12 months of tenure, indicating performance-based compensation tied to investment returns. Synthesis Capital's investment strategy targets strong financial returns alongside positive environmental impact.

synthesis.capital
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Synthesis Capital is a London-based venture capital firm that invests in food technology companies from seed to Series C, with a thematic focus on platforms that replace animal-derived products (alternative proteins, cultivated meat, precision fermentation, and biomanufacturing). The firm manages over $300M in assets under management, leads and co-leads Series A and B rounds, and provides hands-on post-investment support including board leadership, governance, and ESG integration. Revenue is generated through fund management fees on committed capital and carried interest on investment performance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Synthesis Capital Fund I LP has been designated as a Guernsey Green Fund by the GFSC.
+1 more record
Product overview1 text field

Synthesis Capital is a venture capital firm operating as a single unified investment platform rather than a multi-product company. The firm manages $300M+ in assets under management and focuses on leading and co-leading Series A and B funding rounds in food technology companies. Rather than offering distinct product modules, Synthesis Capital provides investment services to its portfolio companies including strategic direction guidance, industry partnership development, and commercialization support. The firm's investment thesis centers on companies that replace animal products across the food supply chain, with portfolio companies including Equinom (computational breeding), Hyfé (carbon waste valorization), Redefine Meat (plant-based meat), Savor (synthetic fats), Pow.Bio (continuous fermentation), New Culture (animal-free dairy), Upside Foods (cultivated meat), Culture Biosciences (bioreactor services), Perfect Day (precision fermentation dairy), and Triplebar (cell screening).

Product and service1 record
1Synthesis Capital Investment Services
CategoryVenture Capital / Private Equity Investment Services
Description

Venture capital investment services to food technology founders and their companies, providing seed to Series C capital, board leadership, governance, and hands-on strategic and ESG support, with over $300M in assets under management.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

Triplebar announced a partnership in January 2023 with global ingredients giant FrieslandCampina to co-develop and scale up the production of ingredients essential to human nutrition via precision fermentation. Triplebar and FrieslandCampina produce microbial cells via fermentation methodologies to create proteins with a much smaller land, water, and energy footprint than traditional livestock.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

In early 2023, Triplebar partnered with cultivated seafood platform company Umami Bioworks to co-develop optimized cell lines suitable for large-scale production of cultivated seafood, starting with Japanese eel. The partnership leverages Triplebar's Hyper-Throughput screening platform to improve the fitness and performance of cell lines without the need for genetic modification.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synthesis Capital

Venture Capital (Food Technology)synthesis.capital

Synthesis Capital is a London-based, FCA-regulated venture capital firm managing $300M+ in assets and focused exclusively on seed-to-Series-C food technology companies developing alternative proteins, fermentation, and synthetic fat platforms to replace animal products.

What Synthesis Capital does

Synthesis Capital LLP is a London-based, FCA-regulated venture capital firm founded in 2020 that invests exclusively in food technology companies from seed through Series C. The firm manages over $300M in assets under management, claims 14+ years of investing experience at the leading edge of food technology, and focuses on technologies that replace animal products across the food supply chain — spanning cultivated meat, plant-based proteins, precision and continuous fermentation, synthetic fats, and cell-line screening.

The firm's product is a single investment platform (Synthesis Capital Fund I LP) deployed across approximately 10 disclosed portfolio companies, including Equinom, Hyfé, Redefine Meat, Savor, Pow.Bio, New Culture, Upside Foods, Culture Biosciences, Perfect Day, and Triplebar. Synthesis Capital typically leads or co-leads Series A and B rounds, partners with high-profile co-investors (Temasek, Abu Dhabi Growth Fund, Breakthrough Energy Ventures, The Production Board), and provides hands-on post-investment support including board leadership and ESG integration. The firm operates with fewer than 10 employees, is co-led by Managing Partner Costa Yiannoulis and Partner Rosie Wardle, and maintains the Guernsey Green Fund designation and UN PRI signatory status as core institutional credibility markers.

Synthesis Capital's revenue model follows the standard venture capital structure: recurring management fees charged on committed capital under investment advisory agreements, supplemented by performance-based carried interest tied to fund returns. The firm does not sell technology products and generates no transactional product revenue; the underlying asset base (AUM), LP composition, and fund performance cycle are the principal value drivers. Distribution and deal sourcing occur through founder networks, co-investor syndicates, and direct outreach, with thought-leadership content and conference presence supporting top-of-funnel brand building.

Synthesis Capital firmographics

Firmographics
Name
Synthesis Capital
Legal name
Synthesis Capital LLP
Website
https://synthesis.capital
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Synthesis Capital is a London-based, FCA-regulated venture capital firm managing $300M+ in assets and focused exclusively on seed-to-Series-C food technology companies developing alternative proteins, fermentation, and synthetic fat platforms to replace animal products.
Ownership category
akta.pro rank

Synthesis Capital industry classification

Industry
Product category
Venture Capital (Food Technology)
NAICS
Other Financial Investment Activities (5239)
akta.pro industry
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)
SECONDARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)

Keywords

  • Venture capital investing
  • Food technology investments
  • Alternative protein funding
  • Impact venture capital
  • Early stage growth capital

Where Synthesis Capital is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Synthesis Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Fund Management Fees: As a venture capital firm managing over $300M in assets under management, Synthesis Capital generates revenue through management fees charged on committed capital under its investment advisory agreements. These fees support the firm's operations and investment activities.
  2. Carried Interest (Performance Fees): The firm operates a long-term carried interest incentive plan for eligible team members after 12 months of tenure, indicating performance-based compensation tied to investment returns. Synthesis Capital's investment strategy targets strong financial returns alongside positive environmental impact.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Synthesis Capital product offering

Product offering

Core offering

Synthesis Capital is a London-based venture capital firm that invests in food technology companies from seed to Series C, with a thematic focus on platforms that replace animal-derived products (alternative proteins, cultivated meat, precision fermentation, and biomanufacturing). The firm manages over $300M in assets under management, leads and co-leads Series A and B rounds, and provides hands-on post-investment support including board leadership, governance, and ESG integration. Revenue is generated through fund management fees on committed capital and carried interest on investment performance.

Product overview

Synthesis Capital is a venture capital firm operating as a single unified investment platform rather than a multi-product company. The firm manages $300M+ in assets under management and focuses on leading and co-leading Series A and B funding rounds in food technology companies. Rather than offering distinct product modules, Synthesis Capital provides investment services to its portfolio companies including strategic direction guidance, industry partnership development, and commercialization support. The firm's investment thesis centers on companies that replace animal products across the food supply chain, with portfolio companies including Equinom (computational breeding), Hyfé (carbon waste valorization), Redefine Meat (plant-based meat), Savor (synthetic fats), Pow.Bio (continuous fermentation), New Culture (animal-free dairy), Upside Foods (cultivated meat), Culture Biosciences (bioreactor services), Perfect Day (precision fermentation dairy), and Triplebar (cell screening).

Differentiator

Problem solved

Functional benefit

Products and services

  • Synthesis Capital Investment Services Venture capital investment services to food technology founders and their companies, providing seed to Series C capital, board leadership, governance, and hands-on strategic and ESG support, with over $300M in assets under management.

Quantifiable outcome

  • Synthesis Capital Fund I LP has been designated as a Guernsey Green Fund by the GFSC.
  • +1 more outcomes

Companies that use Synthesis Capital

Customer profile

Segments2 records

Ideal customer profiles2 records

Synthesis Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Synthesis Capital partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • FrieslandCampina IngredientscoreStrategic or Co-development Partner · 9 January 2023Triplebar announced a partnership in January 2023 with global ingredients giant FrieslandCampina to co-develop and scale up the production of ingredients essential to human nutrition via precision fermentation. Triplebar and FrieslandCampina produce microbial cells via fermentation methodologies to create proteins with a much smaller land, water, and energy footprint than traditional livestock.
  • Umami BioworkscoreStrategic or Co-development Partner · 1 January 2023In early 2023, Triplebar partnered with cultivated seafood platform company Umami Bioworks to co-develop optimized cell lines suitable for large-scale production of cultivated seafood, starting with Japanese eel. The partnership leverages Triplebar's Hyper-Throughput screening platform to improve the fitness and performance of cell lines without the need for genetic modification.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Synthesis Capital competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

Synthesis Capital social profiles

Digital presence

Synthesis Capital compliance and trust

Trust signal

Compliance2 records

Synthesis Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synthesis Capital leadership team

Management profile

Number of profiles

Profiles2 records

Synthesis Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synthesis Capital M&A and investment

M&A and investment

M&A

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synthesis Capital

What does Synthesis Capital do?

Synthesis Capital is a London-based venture capital firm that invests in food technology companies from seed to Series C, with a thematic focus on platforms that replace animal-derived products (alternative proteins, cultivated meat, precision fermentation, and biomanufacturing). The firm manages over $300M in assets under management, leads and co-leads Series A and B rounds, and provides hands-on post-investment support including board leadership, governance, and ESG integration. Revenue is generated through fund management fees on committed capital and carried interest on investment performance.

Is Synthesis Capital a public or private company?

Synthesis Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Synthesis Capital founded?

Synthesis Capital was founded in 2020. It employs 11 to 50 people.

Where is Synthesis Capital based?

Synthesis Capital is headquartered in London, United Kingdom, in the Europe region.

How does Synthesis Capital make money?

Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest (Performance Fees).

Does Synthesis Capital have an API?

No public API is recorded for Synthesis Capital.

What industry is Synthesis Capital in?

Synthesis Capital's product category is Venture Capital (Food Technology). Its primary akta.pro industry code is FSANAAAC, Late-Stage Venture Capital (Series C+), with a secondary code of FSANAAAA, Early-Stage Venture Capital (Pre-Seed/Seed). Its NAICS code is 5239.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynthesisUnlocking the Future of Biomanufacturing with Continuous Fermentation: Why We Invested in Pow.BioSynthesis Capital announced its investment in Pow.Bio's pre-Series B bridge round, backing the company's continuous fermentation platform technology. Pow.Bio has developed a continuous fermentation system that reportedly achieves 50-80% unit cost reductions and two to five times the product output per unit of feedstock compared to traditional fed-batch fermentation, addressing a key cost barrier in biomanufacturing. The investment thesis positions Pow.Bio's bioreactor-agnostic, AI-powered platform as an enabling technology for the alternative protein and broader $800 billion biomanufacturing industry.CNBC38-year-old’s startup, backed by Bill Gates, has raised $33M to reinvent butter without cows: We want ‘to save the world’Savor, a San Jose-based food startup founded in March 2022, has raised $33 million in funding from Bill Gates' Breakthrough Energy Ventures and Synthesis Capital to create cooking fats like butter, palm oil, and cocoa products from carbon without any animals or plants. The company, which operates a 25,000-square-foot pilot facility in Batavia, Illinois, uses nearly century-old science to recreate fats that closely mimic traditional animal and plant-based products, though it currently uses only about 1% of its facility's capacity and products won't reach grocery shelves until at least 2029. Savor is currently focused on supplying its cooking fats as ingredients to restaurant partners and food manufacturers, with plans to expand production once costs decrease and regulatory approval is secured.Snopes.comBill Gates-backed company created lab-made butterSavor, a company that manufactures lab-made butter produced directly from carbon dioxide and hydrogen, launched its product commercially in March 2025. The company is backed by Breakthrough Energy Ventures, a climate technology investment fund founded by Bill Gates in 2015, which became a shareholder in 2022 alongside co-investor Synthesis Capital. Savor has secured $33 million in venture capital funding and is currently seeking FDA approval for its synthetic fat product.American City Business JournalsWomen investing in women: Million-dollar ladiesMaria Cho and Rosie Wardle, leaders in food tech, are highlighted for their partnership between Triplebar and Synthesis Capital. Cho led Triplebar's $21 million fundraising, while Wardle's firm invested, aiming to accelerate sustainable food and health innovations. They target a 2050 vision of accessible food and therapies.PR NewswireIncreasing the Share of Alternative Proteins to Half the Global Protein Market Would Cut Emissions as Much as Taking Half of Gas-Fueled Cars Off the RoadA report by BCG, GFI, and Synthesis Capital finds that growing alternative proteins to half the global protein market would cut agriculture emissions by almost a third by 2050, equivalent to removing 50% of gas cars. Plant-based meat holds only 1% of US retail meat sales, and alternative proteins received $635 million in government support in 2022 versus $40 billion for EVs.LinkedInSynthesis Capital led our Series A financing and just published this comprehensive post outlining the importance of fats in making our food system more resilient and less harmful to the climate.Synthesis Capital led the company's Series A financing and published a post on fats for a more resilient, climate-friendly food system. The post argues that biological systems may not be the most efficient tool for producing meat and dairy ingredients, prompting exploration of alternative fat technologies.Pulse 2.0Hyfé: $9 Million Closed For Creating Future Feedstocks For BiomanufacturingHyfé secured an oversubscribed $9 million seed investment led by Synthesis Capital to advance its technology for converting food processing wastewater into biomanufacturing feedstocks. The company plans to use the funds to expand its workforce, develop commercial partnerships, and progress toward pilot-scale demonstrations of its waste valorization process.SynBioBetaTransforming Food Processing Wastewater: Novel Approach Receives $9M in Seed FundingHyfé, a company founded by former ExxonMobil and LanzaTech engineers, has raised $9 million in an oversubscribed seed funding round to transform food processing wastewater into sustainable feedstocks and clean water. The funding, led by Synthesis Capital, will support the company in advancing partnerships and scaling its technology. The biomanufacturing sector is expected to play a pivotal role in decarbonizing industries and mitigating carbon emissions in the coming years.